Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor
Yet empagliflozin gets a boost from a lower risk of total HF events in EMPACT-HF
Source: medpagetoday.com
Stay updated with breaking news from Patrick Ogara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Yet empagliflozin gets a boost from a lower risk of total HF events in EMPACT-HF
The analysis, for 2013-2021, found a higher death risk at 5 years with TAVI, but some urged caution in interpreting that finding.
Echo data show no signs of deterioration from thrombosis or structural issues, but experts say more follow-up is warranted.
On the streets of Labour’s new constituencies, there was anti-Tory feeling – but also much apathy
The results affirm reductions in TR severity and gains in quality of life compared with medical therapy.